# US 2025/0154595 A1 · Submandibular gland tissue biomarker for diagnosis, prognosis prediction, or treatment of parkinson's disease, method for diagnosing parkinson's disease, or predicting prognosis using the same, and method for screening substances for treating parkinson's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154595 A1
- Document ID: US20250154595A1
- Status: Published application
- Kind: A1
- Application number: 18/941,569
- Filed: 2024-11-08
- Published: 2025-05-15
- Earliest claimed: 2023-11-09
- Assignees: The Catholic University of Korea Industry-Academic Cooperation Foundation
- Applicants: The Catholic University of Korea Industry-Academic Cooperation Foundation
- Inventors: Ko Eun CHOI; Joong-Seok KIM
- Web page: https://patentgrep.com/patent/US20250154595A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Provided are a submandibular gland tissue biomarker for diagnosis, prognosis prediction, or treatment of Parkinson's disease (PD), a method for diagnosing or predicting the prognosis of PD using the same, and a method for screening substances for treating PD, where it has been confirmed that an SNCAIP gene is significantly decreased and the level of 15 types of miRNA is increased in tissues collected from submandibular gland tissues, and thus PD may be diagnosed using the marker, particularly for subject groups in which the presence or absence of PD cannot be determined by α-synuclein, and since the marker reflects the correlation between genes and environmental factors identified in subjects with PD, the marker can be used as a diagnostic and prognostic biomarker, as well as a new therapeutic target for pathological mechanism of PD.

## Claims

### Claim 1

A method comprising the steps of:
(S1) measuring the level of mRNA of an α-synuclein interacting protein (SNCAIP) gene encoding synphilin-1 in a biological sample isolated from a subject;
(S2) comparing the level of the mRNA with the level of the mRNA in a biological sample isolated from a normal control group;
(S3) determining that the subject has Parkinson's disease (PD) when the level of the mRNA in the biological sample isolated from the subject is decreased compared to the level of the mRNA in the biological sample isolated from the control group; and
(S4) treating the PD with chemotherapy, surgery, or biological therapy when PD is diagnosed in step (S3).

### Claim 2 (depends on 1)

The method of claim 1, wherein the biological sample is one selected from the group consisting of submandibular gland tissue, blood, serum, whole blood, plasma, urine, saliva, tissue, cells, organs, bone marrow, a fine needle aspiration specimen, a core needle biopsy specimen, and a vacuum aspiration biopsy specimen.

### Claim 3

A method comprising the steps of:
(S1) measuring the level of any one or more of miRNAs selected from the group consisting of hsa-miR-122-5p, hsa-miR-130b-3p, hsa-miR-148a-3p, hsa-miR-301b-3p, hsa-miR-331-3p, hsa-miR-3651, hsa-miR-375-3p, hsa-miR-376a-5p, hsa-miR-3938, hsa-miR-4449, hsa-miR-4775, hsa-miR-548an, hsa-miR-5690, hsa-miR-580-3p, and hsa-miR-7977 in a biological sample isolated from a subject;
(S2) comparing the level of the miRNA with the level of the miRNA in a biological sample isolated from a normal control group;
(S3) diagnosing that the subject has Parkinson's disease (PD) when the level of the miRNA in the biological sample isolated from the subject is increased compared to the level of the miRNA in the biological sample isolated from the control group; and
(S4) treating the PD with chemotherapy, surgery, or biological therapy when PD is diagnosed in step (S3).

### Claim 4 (depends on 3)

The method of claim 3, wherein the biological sample is one selected from the group consisting of submandibular gland tissue, blood, serum, whole blood, plasma, urine, saliva, tissue, cells, organs, bone marrow, a fine needle aspiration specimen, a core needle biopsy specimen, and a vacuum aspiration biopsy specimen.

### Claim 5

A method comprising the steps of:
(S1) measuring the level of any one or more of miRNAs selected from the group consisting of hsa-miR-130b-3p, hsa-miR-148a-3p, hsa-miR-301b-3p, hsa-miR-331-3p, hsa-miR-375-3p, hsa-miR-376a-5p, hsa-miR-5690, and hsa-miR-580-3p in a biological sample isolated from a subject;
(S2) comparing the level of the miRNA with the level of the miRNA in a biological sample isolated from a normal control group;
(S3) diagnosing that the subject has Parkinson's disease (PD) when the level of the miRNA in the biological sample isolated from the subject is more than 2-fold change increased compared to the level of the miRNA in the biological sample isolated from the control group, and the AUC value is ≥0.5, the p-value is <0.5, the Confidence Limits value falls between 0.001 and 671; and
(S4) treating the PD with chemotherapy, surgery, or biological therapy when PD is diagnosed in step (S3).
